Clinical Trials Browser

Completed × Cholangiocarcinoma × donafenib × Clear all

NCT05348811 2026-01-06

HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

Phase 2 Completed

Gastrointestinal

Cholangiocarcinoma